Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Profit After Tax (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Profit After Tax for 4 consecutive years, with -$20.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Profit After Tax fell 35.02% to -$20.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$75.1 million, a 30.19% decrease, with the full-year FY2024 number at -$61.0 million, down 24.23% from a year prior.
  • Profit After Tax was -$20.8 million for Q3 2025 at Orchestra BioMed Holdings, down from -$19.4 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$5.7 million in Q1 2022 to a low of -$31.7 million in Q4 2022.
  • A 4-year average of -$15.0 million and a median of -$13.5 million in 2024 define the central range for Profit After Tax.
  • Biggest YoY gain for Profit After Tax was 59.63% in 2023; the steepest drop was 90.96% in 2023.
  • Orchestra BioMed Holdings' Profit After Tax stood at -$31.7 million in 2022, then soared by 59.63% to -$12.8 million in 2023, then dropped by 26.03% to -$16.2 million in 2024, then fell by 28.93% to -$20.8 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Profit After Tax are -$20.8 million (Q3 2025), -$19.4 million (Q2 2025), and -$18.8 million (Q1 2025).